BHLHE40-AS1

Summary

BHLHE40-AS1 (BHLHE40 antisense RNA 1, HGNC:44471) is a long non-coding RNA gene on chromosome 3p26.1.

Predicted to be involved in SRP-dependent cotranslational protein targeting to membrane, signal sequence recognition. Predicted to be part of signal recognition particle, endoplasmic reticulum targeting.

Source: NCBI Gene 100507582 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:44471
Approved symbol	BHLHE40-AS1
Name	BHLHE40 antisense RNA 1
Location	3p26.1
Locus type	RNA, long non-coding
Status	Approved
Ensembl gene	ENSG00000235831
Ensembl biotype	lncRNA
Entrez	100507582
RNAcentral	URS00007E4BAC — lncRNA, 2451 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 15 lncRNA

ENST00000441386, ENST00000615017, ENST00000615178, ENST00000620618, ENST00000663474, ENST00000668962, ENST00000701363, ENST00000814314, ENST00000814315, ENST00000814316, ENST00000814317, ENST00000814318, ENST00000814319, ENST00000814320, ENST00000814321

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000441386 — 3 exons

Exon	Start	End
ENSE00001603931	4900541	4900697
ENSE00004215227	4979795	4980414
ENSE00004215230	4896808	4898935

Expression profiles

Bgee: expression breadth ubiquitous, 128 present calls, max score 79.01.

FANTOM5 (CAGE): breadth broad, TPM avg 1.1149 / max 71.1016, expressed in 469 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
40868	0.6257	313
40869	0.3376	145
40854	0.1141	23
40853	0.0266	12
40852	0.0109	6

Top tissues by expression

128 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	79.01	gold quality
vagina	UBERON:0000996	78.28	gold quality
esophagus mucosa	UBERON:0002469	77.76	gold quality
left adrenal gland cortex	UBERON:0035825	72.06	gold quality
left adrenal gland	UBERON:0001234	71.98	gold quality
granulocyte	CL:0000094	71.88	gold quality
right adrenal gland	UBERON:0001233	71.63	gold quality
skeletal muscle tissue	UBERON:0001134	71.25	gold quality
uterine cervix	UBERON:0000002	71.04	gold quality
ectocervix	UBERON:0012249	70.76	gold quality
gall bladder	UBERON:0002110	70.61	gold quality
right adrenal gland cortex	UBERON:0035827	70.16	gold quality
esophagus	UBERON:0001043	69.84	gold quality
adrenal gland	UBERON:0002369	69.82	gold quality
muscle tissue	UBERON:0002385	69.71	gold quality
omental fat pad	UBERON:0010414	69.31	gold quality
bone marrow cell	CL:0002092	69.17	silver quality
thoracic mammary gland	UBERON:0005200	68.93	gold quality
tibial artery	UBERON:0007610	68.81	gold quality
popliteal artery	UBERON:0002250	68.78	gold quality
urinary bladder	UBERON:0001255	68.75	gold quality
cortex of kidney	UBERON:0001225	68.59	gold quality
skin of abdomen	UBERON:0001416	68.54	gold quality
adenohypophysis	UBERON:0002196	68.37	gold quality
mucosa of stomach	UBERON:0001199	68.18	gold quality
minor salivary gland	UBERON:0001830	68.12	gold quality
body of pancreas	UBERON:0001150	67.98	gold quality
saliva-secreting gland	UBERON:0001044	67.76	gold quality
tibial nerve	UBERON:0001323	67.76	gold quality
bone marrow	UBERON:0002371	67.72	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.59

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 1)

• Long noncoding RNA BHLHE40-AS1 promotes early breast cancer progression through modulating IL-6/STAT3 signaling. (PMID:31907974)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.